Zusammenfassung
Retrospektive und prospektive Untersuchungen belegen, dass die Machbarkeit von molekularem Profiling, d. h. der genomischen Charakterisierung von Tumoren, im akademischen und auch im gehobenen Routine-Setting gegeben ist. Die Frage, ob bzw. inwieweit eine auf Basis derartiger Analysen zusammengestellte („matched“) Therapie zu besseren Ergebnissen als Standardtherapie führt, muss als nach wie vor nicht endgültig geklärt eingestuft werden. Die Studien, die einen Vorteil für gematchte Therapie nahelegen, sind retrospektiven Charakters und damit für Bias anfällig. Die bisher einzigen beiden prospektiv randomisierten Studien, die sich dieser Fragestellung angenommen haben, verliefen negativ, und Ergebnisse weiterer prospektiv randomisierter Studien sind noch ausständig. Wenngleich einzelne, meist einarmige Strategiestudien einen Vorteil für Therapie gemäß molekularem Profiling suggerieren, ist die Datenlage bisher nicht reif genug, um ein derartiges Vorgehen oder sogar eine Kommerzialisierung derartiger Testungen jenseits von laufend anzupassenden Behandlungsrichtlinien außerhalb von klinischen Prüfungen, d. h. für die klinische Routine, zu empfehlen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T, FOCUS4 Trial Investigators (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterol Hepatol 3:162–171. https://doi.org/10.1016/S2468-1253(17)30394-1
Adams R, Fisher D, Graham J, Seligmann JF, Seymour M, Kaplan RS, Yates E, Richman SD, Quirke P, Butler R, Brown E, Falk S, Collinson FJ, Wilson RH, Brown LC, Maughan T, FOCUS4 Investigators (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: results from the randomized FOCUS4-N trial. J Clin Oncol 39(Suppl 15):abstr 3504. https://doi.org/10.1200/JCO.2021.39.15_suppl.3504
Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR (2019) SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol 14:1847–1852. https://doi.org/10.1016/j.jtho.2019.05.041
Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O (2019) Application of cell-free DNA for genomic tumor profiling: a feasibility study. Oncotarget 10:1388–1398. https://doi.org/10.18632/oncotarget.26642
Ahn ER, Mangat PK, Garrett-Mayer E, Halabi S, Dib EG, Haggstrom DE, Alguire KB, Alvarez RH, Calfa CJ, Cannon TL, Crilley PA, Gaba AG, Marr AS, Sangal A, Thota R, Antonelli KR, Islam S, Rygiel AL, Bruinooge SS, Schilsky RL (2019) Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 37(Suppl):abstr 9041. https://doi.org/10.1200/JCO.2019.37.15_suppl.9041
Ahn ER, Garrett-Mayer E, Halabi S, Mangat PK, Calfa CJ, Alva AS, Suhag VS, Hamid O, Dotan E, Yang ES-H, Alese OB, Yost KJ, Marr AS, Palmer MC, Thompson FL, Rygiel AL, Anderson ST, Islam S, Schilsky RL (2020) Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 38(Suppl):abstr 4637. https://doi.org/10.1200/JCO.2020.38.15_suppl.4637
Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, Alvarez RH, Kim ES, Yost KJ, Rygiel AL, Antonelli KR, Butler NL, Bruinooge SS, Schilsky RL (2019) Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry study. JCO Precis Oncol 3. https://doi.org/10.1200/PO.19.00124
Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL (2020) Sunitinib in patients with metastatic colorectal cancer (mCRC) with FLT-3 amplification: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Target Oncol 15:743–750. https://doi.org/10.1007/s11523-020-00752-8
Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ, Janeway K, Pediatric MATCH Target and Agent Prioritization Committee (2017) Target and agent prioritization for the Children’s Oncology Group-National Cancer Institute Pediatric MATCH trial. J Natl Cancer Inst 109:djw274. https://doi.org/10.1093/jnci/djw274
Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL (2021) Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol. https://doi.org/10.1200/JCO.20.02923. (online ahead of print)
Andre F, Delaloge S, Soria JC (2011) Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 29:1236–1238. https://doi.org/10.1200/JCO.2010.31.6877
Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C (2014a) Prioritizing targets for precision cancer medicine. Ann Oncol 25:2295–2303. https://doi.org/10.1093/annonc/mdu478
André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adélaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H (2014b) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15:267–274. https://doi.org/10.1016/S1470-2045(13)70611-9
Aparicio T, Cozic N, de la Fouchardière C, Meriaux E, Plaza J, Mineur L, Guimbaud R, Samalin E, Mary F, Lecomte T, Gomez-Roca C, Haineaux PA, Gratet A, Selves J, Menu Y, Colignon N, Johnson L, Legrand F, Vassal G (2021) The activity of crizotinib in chemo-refractory MET-amplified esophageal and gastric adenocarcinomas: results from the AcSé-Crizotinib Program. Target Oncol 16:381–388. https://doi.org/10.1007/s11523-021-00811-8
Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O’Dwyer PJ, Chen AP, Flaherty KT (2020) Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from Arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol 38:214–222. https://doi.org/10.1200/JCO.19.00818
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97–100. https://doi.org/10.1038/clpt.2009.68
Bedard PL, Oza AM, Tsao M-S, Leighl NB, Shepherd FA, Chen EX, Tannock I, Krzyzanowska MK, Dhani NC, Clarke B, Berman HK, Serra S, Craddock KJ, Chadwick D, Zhang T, Sukhai MA, Yu C, Hansen AR, Kamel-Reid S, Siu LL (2013) Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). J Clin Oncol 31(Suppl):abstr 11002. https://doi.org/10.1200/jco.2013.31.15_suppl.11002
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow J, Gray RJ, McShane LM, Rubenstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT (2019) NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations. Cancer Res 79(13 Suppl):abstr CT139. https://doi.org/10.1158/1538-7445.AM2019-CT139
Bernards R (2012) A missing link in genotype-directed cancer therapy. Cell 151:465–468. https://doi.org/10.1016/j.cell.2012.10.014
Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA (2021) SWOG S1400A (NCT02154490): a phase II study of durvalumab for patients with previously treated stage IV or recurrent squamous cell lung cancer (Lung-MAP sub-study). Clin Lung Cancer 22:178–186. https://doi.org/10.1016/j.cllc.2020.10.015
Buxton M, DeMichele AM, Chia S, van’t Veer L, Chien J, Wallace A, Kaplan H, Lang J, Yee D, Isaacs C, Moulder S, Albain K, Boughey J, Kemmer K, Haley B, Minton S, Forero A, Nanda R, Elias A, Korde L, Viscuzi R, Rugo H, Schwab R, Symmans F, Paoloni M, Hylton N, Hogarth M, Lyandres J, Perlmutter J, Sanil A, Yau C, Esserman L, Berry D, I-SPY 2 TRIAL Investigators (2016) Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 TRIAL. Cancer Res 76(14 Suppl):abstr CT106. https://doi.org/10.1158/1538-7445.AM2016-CT106
Buzyn A, Blay J-Y, Hoog-Labouret N, Jimenez M, Nowak F, Le Deley M-C, Pérol D, Cailliot C, Raynaud J, Vassal G (2016) Equal access to innovative therapies and precision cancer care. Nat Rev Clin Oncol 13:385–393. https://doi.org/10.1038/nrclinonc.2016.31
Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC (2016) Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer 16:319–329. https://doi.org/10.1038/nrc.2016.35
Catenacci DV (2015) Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 9:967–996. https://doi.org/10.1016/j.molonc.2014.09.011
Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT (2020) Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH Trial (EAY131) subprotocol W. J Clin Oncol 38:2407–2417. https://doi.org/10.1200/JCO.19.02630
Chan KK-W, Tannock IF (2021) Should basket trials be pathways to drug registration for biomarker-defined subgroups of advanced cancers? J Clin Oncol. https://doi.org/10.1200/JCO.21.00552 (online ahead of print)
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, for the BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. https://doi.org/10.1056/NEJMoa1103782
Chen AP, Kummar S, Moore N, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Sims D, O’Sullivan Coyne G, Rosenberger CL, Simpson M, Raghav KPS, Meric-Bernstam F, Leong S, Waqar S, Foster JC, Konaté MM, Das B, Karlovich C, Lih C-J, Polley E, Simon R, Li M-C, Piekarz R, Doroshow JH (2021) Molecular Profiling-based Assignment of Cancer Therapy (NCI-MPACT): a randomized multicenter phase II trial. JCO Precis Oncol 5:133–144. https://doi.org/10.1200/PO.20.00372
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van’t Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium (2020) MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol 38:1059–1069. https://doi.org/10.1200/JCO.19.01027
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845. https://doi.org/10.1200/JCO.2016.68.1478
Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zweibel J, Arnaldez FI, McShane LM, Li S, Gray RJ, Rubenstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, Kasbari SS, Thind R, Conley BA, O’Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT (2019) Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: phase II trial of palbociclib for CCND1, 2 or 3 amplified tumors. Cancer Res 79(13 Suppl):abstr LB-010. https://doi.org/10.1158/1538-7445.AM2019-LB-010
Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O’Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT (2021) Differential outcomes in codon 12/13 and codon 61 NRAS-mutated cancers in the phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors. Clin Cancer Res 27:2996–3004. https://doi.org/10.1158/1078-0432.CCR-21-0066
Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC (2019) Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 30:365–373. https://doi.org/10.1093/annonc/mdz036
Conley BA, Doroshow JH (2014) Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 41:297–299. https://doi.org/10.1053/j.seminoncol.2014.05.002
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell E, Wright J, Sharon E, Gray RJ, Li S, McShane L, Rubinstein L, Patton DR, Williams PM, Hamilton S, Conley B, Arteaga CL, Harris L, O’Dwyer PJ, Chen A, Flaherty KT (2020) Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophageal HER2-amplified tumours: results of the NCI-MATCH trial (EAY131) subprotocol. Ann Oncol 31(Suppl 4):S479–S480, abstr 553P. https://doi.org/10.1016/j.annonc.2020.08.667
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, KEYNOTE-355 Investigators (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9
Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, TCA Ovarian Cancer Trial Group (2007) A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18:1093–1101. https://doi.org/10.1097/CAD.0b013e3281de727e
Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A (2017) Basket trials in oncology: a trade-off between complexity and efficiency. J Clin Oncol 35:271–273. https://doi.org/10.1200/JCO.2016.69.9751
Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J (2017) Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol 1. https://doi.org/10.1200/PO.16.00046
Bono JS de, Ashworth A (2010) Translating cancer research into targeted therapeutics. Nature 467:543–549. https://doi.org/10.1038/nature09339
DeMichele AM, Moulder S, Buxton M, Yee D, Wallace A, Chien J, Isaacs C, Albain K, Boughey J, Kemmer K, Haley B, Lang J, Kaplan H, Minton S, Forero A, Elias A, Nanda R, Korde L, Schwab R, Melisko M, Sanil A, Hogarth M, Hylton N, Paoloni M, Symmans F, Perlmutter J, Lyandres J, Yau C, Berry D, Esserman L, I-SPY 2 TRIAL Investigators (2016) Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 TRIAL. Cancer Res 76(14 Suppl):abstr CT042. https://doi.org/10.1158/1538-7445.AM2016-CT042
Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM (2018) Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384–388. https://doi.org/10.1001/jamaoncol.2017.5029
Dienstmann R, Jang IS, Bot B, Friend S, Guinney J (2015) Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov 5:118–123. https://doi.org/10.1158/2159-8290.CD-14-1118
Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282. https://doi.org/10.1016/S1470-2045(20)30447-2
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185. https://doi.org/10.1016/S0167-6296(02)00126-1
Dittrich C (1987) Klonieren von soliden Tumoren. Springer, Wien
Dittrich C (2020) Basket trials: from tumour gnostic to tumour agnostic drug development. Cancer Treat Rev 90:102082. https://doi.org/10.1016/j.ctrv.2020.102082
Do K, O’Sullivan Coyne G, Chen AP (2015) An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol 4:31. https://doi.org/10.3978/j.issn.2304-3865.2015.08.01
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271–282. https://doi.org/10.1016/S1470-2045(19)30691-6
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739. https://doi.org/10.1056/NEJMoa1714448
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC (2020a) Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:261–270. https://doi.org/10.1016/S1470-2045(19)30690-4
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V (2020b) Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 383:813–824. https://doi.org/10.1056/NEJMoa2005653
Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS (2019) SWOG S1400C (NCT02154490)-a phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol 14:1853–1859. https://doi.org/10.1016/j.jtho.2019.06.027
Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802–820. https://doi.org/10.1016/j.ejca.2004.01.009
Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL (2020) Cetuximab in patients with breast cancer, non-small cell lung cancer, and ovarian cancer without KRAS, NRAS, or BRAF mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Target Oncol 15:733–741. https://doi.org/10.1007/s11523-020-00753-7
Friedman AA, Letai A, Fisher DE, Flaherty KT (2015) Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 15:747–756. https://doi.org/10.1038/nrc4015
Gainor JF, Curigliano G, Kim D-W, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DS-W, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Clifford C, Zhang H, Turner CD, Subbiah V (2020) Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol 38(Suppl):abstr 9515. https://doi.org/10.1200/JCO.2020.38.15_suppl.9515
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N (2020) Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol 21:121–133. https://doi.org/10.1016/S1470-2045(19)30671-0
Gerber DE, Oxnard GR, Govindan R (2015) ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther 97:447–450. https://doi.org/10.1002/cpt.91
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32. https://doi.org/10.1016/S1470-2045(11)70336-9
Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J (2018) High-throughput architecture for discovering combination cancer therapeutics. JCO Clin Cancer Inf 2. https://doi.org/10.1200/CCI.17.00054
Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE (2015) ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin Cancer Res 21:5439–5444. https://doi.org/10.1158/1078-0432.CCR-15-0354
Gray SW, Cronin A, Bair E, Lindeman N, Viswanath V, Janeway KA (2015) Marketing of personalized cancer care on the web: an analysis of Internet websites. J Natl Cancer Inst 107:djv030. https://doi.org/10.1093/jnci/djv030
Grothey A, Tabernero J, Arnold D, De Gramont A, Ducreux MP, O’Dwyer PJ, van Cutsem E, Bosanac I, Srock S, Mancao C, Gilberg F, Winter J, Schmoll H-J (2018) Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Ann Oncol 29(Suppl 8):viii714–viii715, abstr LBA19. https://doi.org/10.1093/annonc/mdy424.020
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U (2020) Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol 21:1478–1488. https://doi.org/10.1016/S1470-2045(20)30464-2
Gupta R, Garrett-Mayer E, Halabi S, Mangat PK, D’Andre SD, Meiri E, Shrestha S, Warren SL, Ranasinghe S, Schilsky RL (2020) Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: results from the TAPUR study. J Clin Oncol 38(Suppl 4):abstr 132. https://meetinglibrary.asco.org/record/182662/abstract. Zugegriffen am 13.06.2021
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R (2018) Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 36:536–542. https://doi.org/10.1200/JCO.2017.75.3780
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL (2020) Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer 126:3972–3981. https://doi.org/10.1002/cncr.33036
Haslam A, Kim MS, Prasad V (2021) Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Ann Oncol 32:926–932. https://doi.org/10.1016/j.annonc.2021.04.003
Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40–51. https://doi.org/10.1038/nbt.2786
Hazim A, Prasad V (2018) A pooled analysis of published, basket trials in cancer medicine. Eur J Cancer 101:244–250. https://doi.org/10.1016/j.ejca.2018.06.035
Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225 (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14:2717–2725. https://doi.org/10.1158/1078-0432.CCR-07-4575
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA (2015) Lung Master Protocol (Lung-MAP) – a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 21:1514–1524. https://doi.org/10.1158/1078-0432.CCR-13-3473
Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S (2016) Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers. The Oncologist 21:1315–1325. https://doi.org/10.1634/theoncologist.2016-0049
Ho AL, Chau N, Bauman J, Bible K, Chintakuntlawar A, Cabanillas ME, Wong DJ, Braña Garcia I, Brose MS, Boni V, Even C, Razaq M, Mishra V, Bracken K, Wages D, Scholz C, Gualberto A (2018) Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. Ann Oncol 29(Suppl 8):viii373, abstr 1046O. https://doi.org/10.1093/annonc/mdy287.002
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A (2021) Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 39:1856–1864. https://doi.org/10.1200/JCO.20.02903
Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I (1999) Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res 5:2198–2204
Holch JW, Metzeler KH, Jung A, Riedmann K, Jost PJ, Weichert W, Kirchner T, Heinemann V, Westphalen CB (2017) Universal genomic testing: the next step in oncological decision-making or a dead end street? Eur J Cancer 82:72–79. https://doi.org/10.1016/j.ejca.2017.05.034
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A (2020a) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531–540. https://doi.org/10.1016/S1470-2045(19)30856-3
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT (2020b) KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 383:1207–1217. https://doi.org/10.1056/NEJMoa1917239
Horak P (2018) Von Gentests über genomische Sequenzierung zur personalisierten Onkologie. Spectrum Onkol 1:24–26
Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141:877–886. https://doi.org/10.1002/ijc.30828
Hyman DM, Solit DB (2015) Tumor genetic screening programs: a call to action. J Clin Oncol 33:2725–2726. https://doi.org/10.1200/JCO.2015.61.9296
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726–736. https://doi.org/10.1056/NEJMoa1502309
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS (2017a) AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol 35:2251–2259. https://doi.org/10.1200/JCO.2017.73.0143
Hyman DM, Taylor BS, Baselga J (2017b) Implementing genome-driven oncology. Cell 168:584–599. https://doi.org/10.1016/j.cell.2016.12.015
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189–194. https://doi.org/10.1038/nature25475
Institute of Medicine (2010) A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. The National Academies Press, Washington, DC. https://doi.org/10.17226/12879. Zugegriffen am 13.06.2021
Institute of Medicine (2013) Delivering high-quality cancer care: charting a new course for a system in crisis. The National Academies Press, Washington, DC. https://doi.org/10.17226/18359. Zugegriffen am 13.06.2021
I-SPY2 Trial Consortium, (Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van’t Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA) (2020) Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol 6:1355–1362. https://doi.org/10.1001/jamaoncol.2020.2535
Janku F, Jegede O, Puhalla SL, Konstantinopoulos P, Meric-Bernstam F, Mitchell EP, Zwiebel JA, McShane LM, Li S, Rubinstein LV, Doyle LA, Patton D, Conley BA, O’Dwyer PJ, Harris LN, Arteaga C, Williams PM, Hamilton SR, Chen AP, Flaherty KT (2018) NCI-MATCH Arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. Ann Oncol 29(Suppl 8):viii137, abstr 418PD. https://doi.org/10.1093/annonc/mdy279.406
Jänne PA, Rybkin II, Spira AI, Riely GJ, Papadopoulos KP, Sabari JK, Johnson ML, Heist RS, Bazhenova L, Barve M, Pacheco JM, Leal TA, Velastegui K, Cornelius C, Olson P, Christensen JG, Kheoh T, Chao RC, Ou S-HI (2020) KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation. 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics. ENA 2020 Abstract Book: abstr 3LBA. https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000902150. Zugegriffen am 13.06.2021
Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, Savage HM, Scaltriti M, Wilson TR, Wei MC, Hyman DM (2021) Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers. Clin Cancer Res 27:447–459. https://doi.org/10.1158/1078-0432.CCR-20-2657
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT (2019) Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 30:1821–1830. https://doi.org/10.1093/annonc/mdz291
Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT (2020b) Trametinib activity in patients with solid tumors and lymphomas harboring BRAF Non-V600 mutations or fusions: results from NCI-MATCH (EAY131). Clin Cancer Res 26:1812–1819. https://doi.org/10.1158/1078-0432.CCR-19-3443
Johnson ML, Ou SHI, Barve M, Rybkin II, Papadopoulos KP, Leal TA, Velastegui K, Christensen JG, Kheoh T, Chao RC, Weiss J (2020a) KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. In: 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics. ENA 2020 Abstract Book: abstr 4LBA. https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000902140. Zugegriffen am 13.06.2021
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O’Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS (2019) Tumour lineage shapes BRCA-mediated phenotypes. Nature 571:576–579. https://doi.org/10.1038/s41586-019-1382-1
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ (2017) Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 7:596–609. https://doi.org/10.1158/2159-8290.CD-16-1337
Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM (2018) BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:3477–3484. https://doi.org/10.1200/JCO.2018.78.9990
Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O’Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT (2021) Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol 7:271–278. https://doi.org/10.1001/jamaoncol.2020.6741
Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, Stein S, Salvado A (2015) The Signature program: bringing the protocol to the patient. Clin Pharmacol Ther 98:124–126. https://doi.org/10.1002/cpt.126
Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M (2013) Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 31:4562–4568. https://doi.org/10.1200/JCO.2013.50.7905
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250. https://doi.org/10.1200/JCO.2014.56.2728
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1:44–53. https://doi.org/10.1158/2159-8274.CD-10-0010
Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A (2014) The combinatorial complexity of cancer precision medicine. Oncoscience 1:504–509. https://doi.org/10.18632/oncoscience.66
Klute K, Garrett-Mayer E, Halabi S, Mangat PK, Nazemzadeh R, Yost KJ, Butler NL, Perla V, Schilsky RL (2020) Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: results from the TAPUR study. J Clin Oncol 38(Suppl 4):abstr 122. https://meetinglibrary.asco.org/record/182553/abstract. Zugegriffen am 13.06.2021
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715. https://doi.org/10.1038/nrd1470
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006. https://doi.org/10.1001/jama.2014.3741
Krop IE, Jegede O, Grilley-Olson JE, Lauring JD, Hamilton SR, Zwiebel JA, Li S, Rubinstein L, Doyle A, Patton DR, Mitchell EP, Arteaga CL, Conley BA, Sims D, Harris L, Chen AP, Flaherty K (2018) Results from Molecular Analysis for Therapy CHoice (MATCH) arm I: taselisib for PIK3CA-mutated tumors. J Clin Oncol 36(Suppl):abstr 101. https://doi.org/10.1200/JCO.2018.36.15_suppl.101
Kummar S, Li S, Reiss K, Ford JM, Mitchell EP, Zwiebel JA, Takebe N, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Brufsky A, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT (2019) NCI-MATCH EAY131-Z1I: phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. Cancer Res 79(13 Suppl):abstr CT138. https://doi.org/10.1158/1538-7445.AM2019-CT138
Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C (2020) Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 31:412–421. https://doi.org/10.1016/j.annonc.2019.11.018
Lam VK, Papadimitrakopoulou V (2018) Master protocols in lung cancer: experience from Lung Master Protocol. Curr Opin Oncol 30:92–97. https://doi.org/10.1097/CCO.0000000000000433
Lamping M, Benary M, Leyvraz S, Messerschmidt C, Blanc E, Kessler T, Schütte M, Lenze D, Jöhrens K, Burock S, Klinghammer K, Ochsenreither S, Sers C, Schäfer R, Tinhofer I, Beule D, Klauschen F, Yaspo ML, Keilholz U, Rieke DT (2020) Support of a Molecular Tumour Board by an evidence-based decision management system for precision oncology. Eur J Cancer 127:41–51. https://doi.org/10.1016/j.ejca.2019.12.017
Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA (2019) SWOG S1400B (NCT02785913), a phase II study of GDC-0032 (taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (Lung-MAP sub-study). J Thorac Oncol 14:1839–1846. https://doi.org/10.1016/j.jtho.2019.05.029
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520. https://doi.org/10.1056/NEJMoa1500596
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413. https://doi.org/10.1126/science.aan6733
Le Tourneau C, Kamal M, Alt M, Verlingue L, Servois V, Sablin MP, Servant N, Paoletti X (2014) The spectrum of clinical trials aiming at personalizing medicine. Chin Clin Oncol 3:13. https://doi.org/10.3978/j.issn.2304-3865.2014.05.02
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X, SHIVA Investigators (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334. https://doi.org/10.1016/S1470-2045(15)00188-6
Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK (2019) Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 9:1388–1405. https://doi.org/10.1158/2159-8290.CD-19-0442
Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site – when a biomarker defines the indication. N Engl J Med 377:1409–1412. https://doi.org/10.1056/NEJMp1709968
Li BT, Makker V, Buonocore DJ, Offin MD, Olah ZT, Panora E, Shen R, Ho AL, Yaeger R, Iyer G, Ginsberg MS, Ulaner G, Solit DB, Hyman DM, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG (2018a) A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol 36(Suppl):abstr 2502. https://doi.org/10.1200/JCO.2018.36.15_suppl.2502
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG (2018b) Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol 36:2532–2537. https://doi.org/10.1200/JCO.2018.77.9777
Liu S, Nikanjam M, Kurzrock R (2016) Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers. Oncotarget 7:11310–11320. https://doi.org/10.18632/oncotarget.7023
Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19:497–509. https://doi.org/10.1016/S1470-2045(18)30111-6
Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G (2015) Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 33:1000–1007. https://doi.org/10.1200/JCO.2014.58.2007
Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823–837. https://doi.org/10.1016/j.cell.2009.02.024
MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI (2014) Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn 16:660–672. https://doi.org/10.1016/j.jmoldx.2014.06.004
Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL (2018) Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO Precis Oncol 2. https://doi.org/10.1200/PO.18.00122
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr (2020a) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10. https://doi.org/10.1200/JCO.19.02105
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ (2020b) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:1353–1365. https://doi.org/10.1016/S1470-2045(20)30445-9
Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093–1098. https://doi.org/10.1001/jamaoncol.2018.1660
Martin-Liberal J, Rodon J (2017) Clinical research in small genomically stratified patient populations. Eur J Cancer 80:73–82. https://doi.org/10.1016/j.ejca.2017.05.008
Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7:586–595. https://doi.org/10.1158/2159-8290.CD-16-1396
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29:1895–1902. https://doi.org/10.1093/annonc/mdy263
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY (2020) Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol 31:289–294. https://doi.org/10.1016/j.annonc.2019.10.022
Meiri E, Garrett-Mayer E, Halabi S, Mangat PK, Shrestha S, Ahn ER, Osayameh O, Perla V, Schilsky RL (2020) Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 38(Suppl 4): abstr 133. https://meetinglibrary.asco.org/record/182503/abstract. Zugegriffen am 13.06.2021
Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB (2015) Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753–2762. https://doi.org/10.1200/JCO.2014.60.4165
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J (2019) Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20:518–530. https://doi.org/10.1016/S1470-2045(18)30904-5
Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ (2015) The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol 26:2464–2469. https://doi.org/10.1093/annonc/mdv394
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O’Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L (2020) The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 583:807–812. https://doi.org/10.1038/s41586-020-2481-8
Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M, Begum R, Eltahir Z, Wotherspoon A, Teixeira Mendes LS, Hulkki Wilson S, Gillbanks A, Baratelli C, Fotiadis N, Patel A, Braconi C, Valeri N, Gerlinger M, Rao S, Watkins D, Chau I, Starling N (2018) Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Ann Oncol 29:230–236. https://doi.org/10.1093/annonc/mdx631
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G (2019) Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol 30:1985–1991. https://doi.org/10.1093/annonc/mdz407
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491–1505. https://doi.org/10.1016/j.annonc.2020.07.014
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17:717–726. https://doi.org/10.1016/S1470-2045(16)00175-3
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34:2460–2467. https://doi.org/10.1200/JCO.2015.64.8931
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van’t Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6:676–684. https://doi.org/10.1001/jamaoncol.2019.6650
National Research Council (2011) Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. The National Academies Press, Washington, DC. https://doi.org/10.17226/13284. Zugegriffen am 13.06.2021
Oh D-Y, Hamilton E, Hanna D, Beeram M, Lee K-W, Kang Y-K, Chaves J, Lee J-Y, Goodwin R, Vaklavas C, Rha S-Y, Elimova E, Mayordomo J, Ferrario C, Cobleigh M, Fortenberry A, Rowse G, Gray T, Lai R, Meric Bernstam F (2019) Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol 30(Suppl 9):ix22, abstr 61O. https://doi.org/10.1093/annonc/mdz420
Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P Jr, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR (2021) Repair-deficient squamous cell lung cancer: Lung-MAP substudy S1400G. Clin Lung Cancer 22:187–194. https://doi.org/10.1016/j.cllc.2021.01.001
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS (2016) The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 34:3638–3647. https://doi.org/10.1200/JCO.2015.66.0084
Papadimitrakopoulou V, Weber Redman M, Gandara DR, Hirsch FR, Mack PC, Langer CJ, Edelman MJ, Aggarwal C, Socinski MA, Gettinger SN, Waqar SN, Griffin K, Leighl NB, Owonikoko TK, Bradley JD, Ramalingam SS, Stinchcombe T, Blanke CD, Kelly K, Herbst RS (2018) First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. J Clin Oncol 36(Suppl):abstr 9019. https://doi.org/10.1200/JCO.2018.36.15_suppl.9019
Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, for the I-SPY 2 Investigators (2016) Adaptive randomization of neratinib in early breast cancer. N Engl J Med 375:11–22. https://doi.org/10.1056/NEJMoa1513750
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P (2008) Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 100:1204–1214. https://doi.org/10.1093/jnci/djn267
Parsons DW, Janeway KA, Patton D, Coffey B, Williams PM, Hamilton SR, Purkayastha A, Tsongalis GJ, Routbort M, Gastier-Foster JM, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Adamson PC, Mooney MM, Takebe N, Tricoli JV, Seibel N (2019) Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. J Clin Oncol 37(Suppl):abstr 10011. https://doi.org/10.1200/JCO.2019.37.15_suppl.10011
Peguero J, Sohal DPS, O’Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD Kang BP, Eder JP (2019) Tissue/site-agnostic study of ribociclib for tumors with cyclin D–CDK4/6 pathway genomic alterations: a phase II, open-label, single-arm basket study. JCO Precis Oncol 3. https://doi.org/10.1200/PO.18.00383
Péron J, Marreaud S, Staelens D, Raveloarivahy T, Nzokirantevye A, Flament J, Steuve J, Lia M, Collette L, Schöffski P (2019) A multinational, multi-tumour basket study in very rare cancer types: the European Organization for Research and Treatment of Cancer phase II 90101 ‚CREATE‘ trial. Eur J Cancer 109:192–195. https://doi.org/10.1016/j.ejca.2018.12.013
Pisick EP, Garrett-Mayer E, Halabi S, Mangat PK, Yang ES-H, Dib EG, Burgess EF, Zakem MH, Rohatgi N, Bilen MA, Warren SL, Anderson ST, Rygiel AL, Schilsky RL (2020) Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 38(Suppl):abstr 5567. https://doi.org/10.1200/JCO.2020.38.15_suppl.5567
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O’Donnell PH (2017) Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18:212–220. https://doi.org/10.1016/S1470-2045(17)30007-4
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100–103. https://doi.org/10.1038/nature10868
President’s Council of Advisors on Science and Technology (PCAST) (2008) Priorities for personalized medicine: report of the President’s Council of Advisors on Science and Technology. http://oncotherapy.us/pdf/PM.Priorities.pdf. Zugegriffen am 13.06.2021
Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP (2018) Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting. JAMA 320:469–477. https://doi.org/10.1001/jama.2018.9824
Pusztai L, Han HS, Yau C, Wolf D, Wallace AM, Shatsky R, Helsten T, Boughey JC, Haddad T, Stringer-Reasor E, Falkson C, Chien AJ, Mukhtar R, Elias A, Virginia B, Nanda R, Yee D, Kalinsky K, Albain KS, Muller AS, Kemmer K, Clark AS, Isaacs C, Thomas A, Hylton N, Symmans WF, Perlmutter J, Melisko M, Rugo HS, Schwab R, Wilson A, Singhrao R, Asare S, van’t Veer LJ, DeMichele AM, Sanil A, Berry DA, Esserman LJ, Trial Consortium I-SPY 2 (2020) Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: results from the I-SPY 2 TRIAL. Cancer Res 80(16 Suppl):abstr CT011. https://doi.org/10.1158/1538-7445.AM2020-CT011
Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O’Neil BH, Schneider BP (2016) Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget 7:56491–56500. https://doi.org/10.18632/oncotarget.10606
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS (2020) Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol 21:1589–1601. https://doi.org/10.1016/S1470-2045(20)30475-7
Renfro LA, Sargent DJ (2017) Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 28:34–43. https://doi.org/10.1093/annonc/mdw413
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R (2019) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med 25:751–758. https://doi.org/10.1038/s41591-019-0424-4
Rugo HS, Olopade OI, Demichele A, Yau C, van Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, on behalf of the I-SPY 2 Investigators (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375:23–34. https://doi.org/10.1056/NEJMoa1513749
SAFIR02 Breast NCT02299999. SAFIR02_Breast – Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients with Metastatic Breast Cancer. https://clinicaltrials.gov. Zugegriffen am 13.06.2021
SAFIR02 Lung NCT02117167. SAFIR02_Lung – Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients. https://clinicaltrials.gov. Zugegriffen am 13.06.2021
Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT (2020) Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol 38:3895–3904. https://doi.org/10.1200/JCO.20.00762
Salmon SE, Alberts DS, Meyskens FL Jr, Durie BGM, Jones SE, Soehnlen B, Young L, Chen HSG, Moon TE (1980) Clinical correlations of in vitro drug sensitivity, Kapitel 18. In: Salmon SE (Hrsg) Cloning of human tumor stem cells. Alan R. Liss, New York, S 223–245
Schmoll HJ (2018) FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer? Lancet Gastroenterol Hepatol 3:143–145. https://doi.org/10.1016/S2468-1253(17)30402-8
Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O’Dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J (2018) MODUL – a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol 144:1197–1204. https://doi.org/10.1007/s00432-018-2632-6
Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L (2017a) Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer 87:147–163. https://doi.org/10.1016/j.ejca.2017.10.014
Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S (2017b) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‚CREATE‘. Ann Oncol 28:3000–3008. https://doi.org/10.1093/annonc/mdx527
Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S (2018a) Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‚CREATE‘. Ann Oncol 29:758–765. https://doi.org/10.1093/annonc/mdx774
Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ (2018b) The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‚CREATE‘. Eur J Cancer 94:156–167. https://doi.org/10.1016/j.ejca.2018.02.011
Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A (2018c) Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med 6:431–441. https://doi.org/10.1016/S2213-2600(18)30116-4
Schram AM, Berger MF, Hyman DM (2017) Precision oncology: charting a path forward to broader deployment of genomic profiling. PLoS Med 14:e1002242. https://doi.org/10.1371/journal.pmed.1002242
Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R (2016) Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. Mol Cancer Ther 15:743–752. https://doi.org/10.1158/1535-7163.MCT-15-0795
Seet AOL, Tan AC, Tan TJ, Ng MCH, Tai DWM, Lam JYC, Tan GS, Gogna A, Too CW, Tan BS, Takano A, Lim A, Lim TH, Lim ST, Dent RA, Ang MK, Yap Y-S, Tan IBH, Choo SP, Toh CK, Lim EH, Farid M, Skanderup AJ, Iyer NG, Lim WT, Tan EH, Lim TKH, Tan DSW (2021) Individualized molecular profiling for allocation to clinical trials Singapore study – an Asian Tertiary Cancer Center experience. JCO Precis Oncol 5:859–875. https://doi.org/10.1200/PO.20.00261
Singh H, Walker AJ, Amiri-Kordestani L, Cheng J, Tang S, Balcazar P, Barnett-Ringgold K, Palmby TR, Cao X, Zheng N, Liu Q, Yu J, Pierce WF, Daniels SR, Sridhara R, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R (2018) U.S. Food and Drug Administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer. Clin Cancer Res 24:3486–3491. https://doi.org/10.1158/1078-0432.CCR-17-3628
Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A (2019) How liquid biopsies can change clinical practice in oncology. Ann Oncol 30:1580–1590. https://doi.org/10.1093/annonc/mdz227
Siu LL, Conley BA, Boerner S, LoRusso PM (2015) Next-generation sequencing to guide clinical trials. Clin Cancer Res 21:4536–4544. https://doi.org/10.1158/1078-0432.CCR-14-3215
Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S, Piha-Paul SA, Salvado A (2018) Signature program: a platform of basket trials. Oncotarget 9:21383–21395. https://doi.org/10.18632/oncotarget.25109
Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL (2016) Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 8:109. https://doi.org/10.1186/s13073-016-0364-2
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 36:7–13. https://doi.org/10.1200/JCO.2017.73.6785
Subbiah V, Gervais R, Riely G, Hollebecque A, Blay JY, Felip E, Schuler M, Gonçalves A, Italiano A, Keedy V, Chau I, Puzanov I, Raje NS, Meric-Bernstam F, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM (2019) Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol 3. https://doi.org/10.1200/PO.18.00266
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM (2020a) Efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers. Cancer Discov 10:657–663. https://doi.org/10.1158/2159-8290.CD-19-1265
Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA (2020b) Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21:1234–1243. https://doi.org/10.1016/S1470-2045(20)30321-1
Subbiah V, Hu MI-N, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Lopez PG, Amatu A, Doebele RC, Cassier PA, Keam B, Schuler MH, Zhang H, Clifford C, Palmer M, Green J, Turner CD, Curigliano G (2020c) Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol 38(Suppl):abstr 109. https://doi.org/10.1200/JCO.2020.38.15_suppl.109
Swanton C (2012) Intratumor heterogeneity: evolution through space and time. Cancer Res 72:4875–4882. https://doi.org/10.1158/0008-5472.CAN-12-2217
Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F (2016) Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol 27:1443–1448. https://doi.org/10.1093/annonc/mdw192
Tannock IF, Hickman JA (2016) Limits to personalized cancer medicine. N Engl J Med 375:1289–1294. https://doi.org/10.1056/NEJMsb1607705
Targeted Agent and Profiling Utilization Registry (o. J.) (TAPUR)-Study. https://www.tapur.org. Zugegriffen am 13.06.2021
Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M (2016) Clinical development success rates 2006–2015. https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical.DevelopmentSuccessRates2006-2015-BIOBiomedtrackerAmplion2016.pdf. Zugegriffen am 13.06.2021
Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY, ProfiLER Investigators (2019) Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol 30:757–765. https://doi.org/10.1093/annonc/mdz080
Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R (2012) Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18:6373–6383. https://doi.org/10.1158/1078-0432.CCR-12-1627
Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D (2014) Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 20:4827–4836. https://doi.org/10.1158/1078-0432.CCR-14-0603
Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R (2019) Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol 12:145. https://doi.org/10.1186/s13045-019-0835-1
Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Gevensleben H, Cutts R, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Martin S, Wilkinson K, Moretti L, Bliss JM, Ring A (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol 21:1296–1308. https://doi.org/10.1016/S1470-2045(20)30444-7
Velden DL van der, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE (2019) The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574:127–131. https://doi.org/10.1038/s41586-019-1600-x
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. https://doi.org/10.1056/NEJMoa1209124
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558. https://doi.org/10.1126/science.1235122
Hoff DD von, Kronmal R, Salmon SE, Turner J, Green JB, Bonorris JS, Moorhead EL, Hynes HE, Pugh RE, Belt RJ, Alberts DS (1991) A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 67:20–27
Hoff DD von, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877–4883. https://doi.org/10.1200/JCO.2009.26.5983
Walker I, Newell H (2009) Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 8:15–16. https://doi.org/10.1038/nrd2758
Wang H, Yee D (2019) I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep 11:303–310. https://doi.org/10.1007/s12609-019-00334-2
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA (2021) A phase II study of telisotuzumab vedotin in patients with c-MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP sub-study S1400K, NCT03574753). Clin Lung Cancer 22:170–177. https://doi.org/10.1016/j.cllc.2020.09.013
Weinstein IB (2002) Addiction to oncogenes – the Achilles heal of cancer. Science 297:63–64. https://doi.org/10.1126/science.1073096
Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080. https://doi.org/10.1158/0008-5472.CAN-07-3293
West HJ (2016) Can we define and reach precise goals for precision medicine in cancer care? J Clin Oncol 34:3595–3596. https://doi.org/10.1200/JCO.2016.68.8226
Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R (2016) Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res 76:3690–3701. https://doi.org/10.1158/0008-5472.CAN-15-3043
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383:825–835. https://doi.org/10.1056/NEJMoa2005651
Woodcock J, LaVange LM (2017) Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 377:62–70. https://doi.org/10.1056/NEJMra1510062
Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F (2018) The European Society for Medical Oncology (ESMO) precision medicine glossary. Ann Oncol 29:30–35. https://doi.org/10.1093/annonc/mdx707
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23:703–713. https://doi.org/10.1038/nm.4333
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Dittrich, C. (2021). Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_389-1
Download citation
DOI: https://doi.org/10.1007/978-3-662-46764-0_389-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46764-0
Online ISBN: 978-3-662-46764-0
eBook Packages: Springer Referenz Medizin